SAB Biotherapeutics Seeks Shareholder Nod for Major Dilution, Equity Boost

TL;DR

**SABSW is asking shareholders to approve massive dilution and a huge equity plan expansion, which is a clear negative for current common stock holders.**

AI Summary

SAB Biotherapeutics, Inc. (SABSW) is calling a Special Meeting on September 26, 2025, to address two critical proposals impacting its capital structure and equity incentive plan. The first proposal seeks stockholder approval for the potential issuance of common stock exceeding 19.99% of its outstanding shares upon conversion of Series B Convertible Preferred Stock, potentially at less than the Nasdaq 'minimum price' and possibly triggering a 'change of control' under Nasdaq Listing Rule 5635. The second proposal aims to amend the 2021 Omnibus Equity Incentive Plan, increasing the maximum shares available to participants by 24,180,000 to an aggregate of 31,932,466 shares, and significantly boosting the annual evergreen increase from 10,000,000 to 73,750,000 shares. These actions are crucial for the company's financing and employee retention strategies, but carry substantial dilution risks for existing common stockholders.

Why It Matters

This DEF 14A filing is a red flag for SAB Biotherapeutics investors, signaling significant potential dilution from the Series B Preferred Stock conversion and a massive increase in the equity incentive pool. For existing common stockholders, this could severely depress per-share value and voting power. Employees, particularly executives, stand to benefit from the expanded equity plan, potentially aligning their interests with long-term growth, but at the cost of current shareholder value. In a competitive biotech landscape, such moves often indicate a need for capital or a strategy to retain talent, but the scale of potential dilution demands close scrutiny from the market.

Risk Assessment

Risk Level: high — The risk level is high due to two primary factors: the potential issuance of common stock in excess of 19.99% upon Series B Preferred Stock conversion at less than the Nasdaq 'minimum price,' which inherently dilutes existing common shareholders. Furthermore, the proposed amendment to the 2021 Omnibus Equity Incentive Plan to increase available shares by 24,180,000 to 31,932,466 and the annual evergreen increase from 10,000,000 to 73,750,000 shares represents a substantial future dilution risk.

Analyst Insight

Investors should vote AGAINST both proposals to protect their existing equity value and demand more favorable terms for any necessary capital raises or incentive plans. Consider reducing exposure to SABSW given the significant dilution risks outlined in this filing.

Key Numbers

• 19.99% — Threshold for potential common stock issuance (Issuance upon Series B conversion may exceed this, triggering Nasdaq rules.)
• 24,180,000 — Increase in shares for 2021 Omnibus Equity Incentive Plan (Adds to the maximum number of shares available for participants.)
• 31,932,466 — Aggregate shares available for 2021 Omnibus Equity Incentive Plan (New total after proposed amendment.)
• 10,000,000 — Current annual evergreen increase for Plan (Proposed to be significantly increased.)
• 73,750,000 — Proposed annual evergreen increase for Plan (Massive increase in potential future share issuance.)
• 10,411,061 — Shares of Common Stock outstanding (As of the Record Date, August 25, 2025.)
• 688 — Shares of Series A Preferred Stock entitled to vote (Limited by 'blocker' provision, convertible into 688,000 common shares.)
• 11,099,061 — Total shares entitled to vote (as-converted) (For Series B Nasdaq Conversion Proposal and Plan Amendment Proposal.)

Key Players & Entities

• SAB Biotherapeutics, Inc. (company) — Registrant and issuer of securities
• Samuel J. Reich (person) — Chief Executive Officer and Chairman of the Board
• Nasdaq (regulator) — Governing listing rules 5635(d) and 5635
• Continental Stock Transfer & Trust Company (company) — Transfer agent for SAB Biotherapeutics
• $0.0001 (dollar_amount) — Par value per share for Common Stock and Series B Convertible Preferred Stock
• $6.30 (dollar_amount) — Conversion price per share for Series A Preferred Stock
• $1,000 (dollar_amount) — Stated value per share for Series A Preferred Stock

FAQ

Risk Factors

• Nasdaq Listing Rule Violations [high — regulatory]: The potential issuance of common stock upon conversion of Series B Preferred Stock may exceed 19.99% of outstanding shares and could be at a price below the Nasdaq 'minimum price'. This could trigger a 'change of control' under Nasdaq Listing Rule 5635, potentially leading to delisting if not approved.
• Significant Dilution Risk [high — financial]: Approval of the Series B Nasdaq Conversion Proposal and the Plan Amendment Proposal will result in substantial dilution for existing common stockholders. The equity incentive plan amendment alone increases the aggregate shares available to 31,932,466 and the annual evergreen increase to 73,750,000 shares, significantly expanding the potential share count.
• Equity Incentive Plan Expansion [medium — financial]: The proposed amendment to the 2021 Omnibus Equity Incentive Plan seeks to increase the maximum shares available by 24,180,000 to 31,932,466. Furthermore, the annual 'evergreen' increase is proposed to jump from 10,000,000 to 73,750,000 shares, representing a substantial increase in future equity dilution potential.

Industry Context

SAB Biotherapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on equity financing and incentive plans to attract and retain specialized talent and fund research and development. The industry is characterized by long development cycles, significant regulatory hurdles, and the potential for high rewards but also substantial risks.

Regulatory Implications

The company faces significant regulatory implications related to Nasdaq Listing Rules. Failure to obtain stockholder approval for the Series B conversion proposal could result in the company issuing shares in violation of Nasdaq Rule 5635, potentially leading to delisting. The proposed equity incentive plan amendments also require careful consideration of dilution impacts on existing shareholders.

What Investors Should Do

1. Review the dilution impact of both proposals carefully.
2. Understand the implications of potential Nasdaq Rule 5635 violations.
3. Evaluate the necessity of the increased equity pool for employee retention and recruitment.

Key Dates

• 2025-09-26: Special Meeting of Stockholders — Stockholders will vote on critical proposals regarding capital structure and equity incentives, including potential share issuances exceeding 19.99% and amendments to the equity incentive plan.
• 2025-08-25: Record Date for Special Meeting — Establishes the list of stockholders entitled to vote at the Special Meeting on September 26, 2025.

Glossary

Series B Convertible Preferred Stock

A class of preferred stock that can be converted into a predetermined number of common stock shares. (Conversion of this stock is a key proposal, potentially leading to significant share issuance and triggering Nasdaq rules.)

2021 Omnibus Equity Incentive Plan

A company plan that allows for the granting of stock options, restricted stock, and other equity-based awards to employees and directors. (The proposed amendment significantly increases the number of shares available under this plan, impacting future dilution.)

Nasdaq Listing Rule 5635

Rules governing when shareholder approval is required for certain equity issuances, including those that could result in a change of control or involve significant dilution. (The proposed Series B conversion may violate this rule if not approved by stockholders, potentially impacting the company's Nasdaq listing.)

Evergreen Increase

A provision in equity incentive plans that automatically replenishes the number of shares available for grant each year, typically by a fixed percentage or number. (The proposed increase from 10,000,000 to 73,750,000 shares annually represents a substantial acceleration of potential future dilution.)

Change of Control

An event that results in a change in the ownership or control of a company, often triggering certain contractual obligations or regulatory requirements. (The Series B conversion, if it results in a significant shift in ownership or voting power, could be deemed a 'change of control' under Nasdaq rules.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, not an annual report, and therefore does not provide comparative financial metrics like revenue growth or margin changes from a previous year. The focus is on upcoming shareholder votes concerning capital structure adjustments and equity incentive plan amendments, highlighting potential dilution and regulatory compliance issues rather than historical financial performance.

Key Financial Figures

• $0.0001 — 9;s outstanding Common Stock, par value $0.0001 per share (the “Common Stock&#x2
• $6.30 — k basis, based on a conversion price of $6.30 per share 1 and stated value of $1,
• $1,000 — .30 per share 1 and stated value of $1,000 per share. The voting of the Series A P
• $1.75 — Common Stock, at a conversion price of $1.75 per Conversion Share (the “Conve

Filing Documents

• sabs_def14a_series_b_xxb.htm (DEF 14A) — 716KB
• img237283619_0.jpg (GRAPHIC) — 125KB
• img237283619_1.jpg (GRAPHIC) — 5KB
• img237283619_2.jpg (GRAPHIC) — 7KB
• img237283619_3.jpg (GRAPHIC) — 5KB
• img237283619_4.jpg (GRAPHIC) — 477KB
• img237283619_5.jpg (GRAPHIC) — 166KB
• 0001193125-25-192856.txt ( ) — 1798KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 HOUSEHOLDING OF PROXY MATERIALS 17 OTHER MATTERS 17 WHERE YOU CAN FIND ADDITIONAL INFORMATION 18 APPENDIX A: AMENDMENT TO THE 2021 OMNIBUS EQUITY INCENTIVE PLAN 22 777 W 41 st Street Suite 401 Miami Beach, Florida 33140 PROXY STATEMENT INFORMATION ABOUT THE SPECIAL MEETING AND VOTING The enclosed proxy is solicited by the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (“SAB,” “we,” “our,” “us” or “the Company”) to be voted at our Special Meeting of Stockholders (the “Special Meeting”) to be held on September 26, 2025 at 10:00 AM Eastern Time in a virtual meeting format only at www.virtualshareholdermeeting.com/SABS2025SM. The Board knows of no matters to come before the Special Meeting other than those described in this Proxy Statement. If any other matters properly come before the Special Meeting (or any adjournment thereof), the persons named in the proxy card as proxies will vote on such matters in their discretion in accordance with their best judgment. Matters to be Voted on at the Special Meeting. At the Special Meeting, the stockholders of the Company will be asked to consider and take action on the following proposals: (1) to approve the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock, par value $0.0001 per share (the “Common Stock”) upon the conversion of the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the

View Full Filing

View this DEF 14A filing on SEC EDGAR